Evora Biosciences is focused on developing novel anti-inflammatory peptides, with its lead asset being EVO-003. This patented peptide demonstrates significant anti-inflammatory potency and is designed for use as an immunomodulatory drug. EVO-003 specifically targets TLR4, a validated receptor implicated in Acute Respiratory Distress Syndrome (ARDS), a condition characterized by severe lung inflammation and high mortality rates. The peptide's selective anti-inflammatory effects, stability, and non-toxic profile make it a promising candidate for various formulations aimed at treating ARDS, a condition for which there are currently no effective therapies.

The company emphasizes the urgent medical need for effective treatments for ARDS, as it accounts for a substantial percentage of ICU admissions and has a high mortality rate. In vivo studies have shown that EVO-003 can lead to significant recovery from ARDS symptoms, positioning it as a first-in-class therapeutic approach. Evora Biosciences aims to leverage its innovative peptide technology to address this critical healthcare challenge, potentially improving outcomes for patients suffering from severe lung inflammation.

France

Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need.

Evora Biosciences

Company Details